格隆汇1月29日丨中国同辐(01763.HK)公告，以下公告的中文原稿由中国同辐股份有限公司旗下一间于 全国中小企业股份转让系统上市的附属公司，原子高科股份有限公司(股份代号：430005)于中国境内发 布。 近日，原子高科股份有限公司(以下简称：原子高科)利用30MeV质子回旋加速器，首次实现放射性核素 锗-68的国产规模化制备，各项指标均符合欧美商业化产品核素要求，这标志着我国正式具备自主、稳 定的锗-68规模化生产能力，为肿瘤患者精准诊断治疗带来福音。目前，世界上仅有少数国家攻克了 锗-68的规模化制备技术。 锗-68是放射性核素镓-68的母体核素，通过衰变生成镓-68。镓-68标记的放射性药物，在核医学领域可 以用于肿瘤的正电子扫描(PET)诊断显像，能够为肿瘤临床诊断治疗提供重要依据。目前，国外已有多 款镓-68药物获批上市用于癌症的诊断，国内亦有13款镓-68药物进入了临床。随着镓-68药物的获批和大 量使用，锗-68在国内外市场的应用前景广阔。 今后，原子高科将持续深耕核医学领域，聚焦重大疾病诊疗需求，加大核素药物研发与技术创新投入， 以更优质的产品与服务助力精准医疗发展，为守护人民健康筑起更坚 ...

Core Viewpoint - The company, Berry Genomics, anticipates a net loss for 2025, projecting a net profit attributable to shareholders between -250 million to -170 million yuan, compared to -192 million yuan in 2024 [1][2] Financial Performance - The company expects a net loss of 165 million to 245 million yuan after deducting non-recurring items for 2025, with a corresponding loss of 192 million yuan in 2024 [1] - Revenue has declined during the reporting period, although operating cash flow remains stable [1] Asset Management - Berry Genomics has conducted a comprehensive review and impairment testing of its assets based on prudence, which has impacted the current net profit [1] - The company has increased its R&D investment, which has led to higher expenses affecting the current net profit [1] Business Focus - The main business of Berry Genomics includes gene testing services and related equipment, focusing on reproductive health, genetic disease testing, and technology services [1] - The company aims to integrate gene testing technology with artificial intelligence algorithms to drive innovation in precision medicine, which is expected to generate revenue [2] Market Position - The newborn gene screening business is progressing as expected, which is anticipated to positively impact the company's business layout in reproductive health [2] - From 2021 to 2024 and the first three quarters of 2025, the company's net profit, net profit attributable to shareholders, and net profit after deducting non-recurring items have consistently been negative [2] Shareholder Issues - Recently, the controlling shareholder, Gao Yang, faced a default in stock pledge repurchase business, resulting in the forced execution of 3.5352 million shares, accounting for 0.999% of the company's total share capital [2]

Group 1: Company Overview - Mirxes, a Singapore-based RNA biotechnology company, is the only listed early screening enterprise in Asia, focusing on the development and commercialization of non-invasive blood miRNA tests for early cancer detection [3] - The company has a rich product pipeline, including products for gastric, lung, colorectal, and breast cancer screening, with the colorectal cancer screening product expected to launch soon [3] - Mirxes has received regulatory approval for its core product, the miRNA-based gastric cancer screening test, marking a significant milestone in its commercialization journey [3] Group 2: Recent Developments - On January 29, Mirxes announced the completion of a new share placement, issuing 21.88 million shares, which represents approximately 7.34% of the expanded share capital, raising about HKD 711 million at a price of HKD 32.5 per share, a nearly 40% premium over its IPO price [1] - The funds raised will focus on core strategic development areas, including investment and acquisition activities, continuous R&D upgrades, accelerated global commercialization, and optimization of the technology innovation platform [1] - Mirxes signed a strategic cooperation memorandum with Jingtai Technology to create an AI-enabled integrated diagnosis and treatment platform, leveraging its advantages in cancer data and early detection [4] Group 3: Industry Context - The global cancer early screening sector is entering a phase of deep integration between capital and industry, with significant growth potential, as evidenced by major investments and acquisitions from international healthcare giants [2] - Policies and payment systems worldwide are increasingly favoring early screening, with the U.S. pushing for multi-cancer early detection products to be included in federal insurance reimbursements, and China incorporating various tumor screenings into its healthcare insurance [2] - The commercialization potential of global cancer early screening products is entering a concentrated release phase, supported by both clinical and market recognition [2] Group 4: Competitive Position - Mirxes has established a strong competitive edge in the Hong Kong biopharmaceutical sector, characterized by its unique regulatory approval for molecular gastric cancer screening and a clear technological barrier [4] - The company is well-positioned in the rapidly growing cancer early screening and precision medicine market, supported by its solid technical foundation, diverse product pipeline, and strategic industry collaborations [4]

作为唯一一家亚洲上市早筛企业，Mirxes觅瑞是一家以新加坡为总部的RNA生物科技公司，深耕东 南亚及东亚市场，致力于开发及商业化针对癌症及其他疾病早期筛查的精准、无创、可负担的血液 miRNA检测，是全球首家且唯一一家获得分子胃癌筛查IVD产品监管批准的公司。不仅如此， Mirxes觅瑞的产品管线丰富，已形成商业化落地、临床推进、临床前研发的梯队布局。除核心胃癌 筛查产品外，公司肺癌、结直肠癌、乳腺癌等单癌种早筛产品均处于有序研发推进阶段，其中结直肠 癌筛查产品有望于近期上市。同时，公司前瞻性布局CADENCE多癌种多组学检测项目，全面覆盖癌 症早筛领域的多元化市场需求。凭借丰富且梯度化的产品管线布局，公司未来增长空间巨大。核心产 品觅小卫®成功获得中国国家药品监督管理局第三类医疗器械注册证，这一里程碑式的成果充分印证 公司技术路径与商业化逻辑正稳步兑现。乘着行业发展的东风，依托自身扎实的综合实力与持续兑现 的成长验证，觅瑞必将在精准医疗的浪潮中稳步前行，不断开拓创新，擘画属于自身的伟大前程，为 全球癌症防控事业创造更深远的价值。 近期，Mirxes觅瑞发布公告，与晶泰科技正式签署战略合作谅解备忘录，瞄准亚 ...

今日，Mirxes正式宣布新股配售，预计筹资约7亿港元。据统计，若此次募资顺利进行，则在短短8个月 内Mirxes已累计募集资金近20亿港元。这是一个清晰的信号：在精准医疗的浪潮中，市场正在用真金白 银投票，选出他们认为能在癌症早筛赛道定义游戏规则的潜力标的。 一、资本的逻辑：为何是它？ 深究其逻辑，Mirxes至少向市场证明了四个具备吸引力的价值基点，构成了其吸引近20亿港元融资的核 心支撑： 1. 说到做到，执行力就是最好的信用 在充满不确定性的18A企业中，"预期管理"和"兑现能力"是衡量管理层可靠性的金标准。Mirxes自招股 书披露以来，所承诺的关键里程碑——无论是核心产品的注册审批，还是重要区域的商业合作——均在 既定时间内稳步推进或达成。这种"说到做到"的纪录，为投资者注入了强劲的信心，证明其并非在"讲 故事"，而是在"干实事"。在当下市场，这种执行力本身就是重要的安全垫和价值支撑。 2. 占据黄金赛道，模式清晰 稀缺的数据资产：在深耕东南亚及大中华区的过程中，公司系统性地积累了亚洲最大、最相关的癌症早 筛真实世界数据库。这不仅是算法迭代的燃料，更是未来与药企合作、开发诊疗一体化方案的基石，构 ...

该院晶格放疗的成功实施，是坚持肿瘤规范化治疗、推动医疗技术创新的重要成果。未来，肿瘤科将不 断引进开展新项目、新技术，为更多晚期肿瘤患者量身打造专属治疗方案，以精准医疗为生命护航。 晚期癌症患者因肿瘤迅速生长，体积较大，压迫、浸润周围器官，传统治疗手段治疗效果不佳，治疗之 路一度陷入僵局。肿瘤科积极探索新疗法，一致认为晚期直肠癌肝转移，肿块巨大时，传统治疗往往面 临两难选择，加大剂量可能损伤健康肝组织，降低剂量又难以遏制肿瘤进展。而空间放疗（晶格放疗） 是一种前沿的空间分割放疗技术，不同于传统放疗的"均匀覆盖"模式，晶格放疗在肿瘤内部构建成一个 个立体的高剂量晶格区域，更像是精准安排的"定点爆破"。 这些"能量晶格"既能形成叠加效应，对肿瘤细胞产生强效杀伤作用，又能在彼此之间保留低剂量区域， 为周围正常组织提供保护通道，发挥"精准杀伤+器官保护"的双重优势。对于肿瘤体积超过5厘米的患 者，能够克服常规放疗的剂量瓶颈。 空间放疗作为打破困局的最优选择，该院肿瘤科决定向"精准放疗"发起冲击。治疗方案确定后，刘元照 教授团队从患者的定位、勾画靶区、计划制定、验证及实施的各个环节全程跟踪指导，确保每一道射线 都精准命 ...

Core Insights - Nancy Pelosi's stock trading performance has yielded an astonishing return of 16,930% over her 30-year congressional career, significantly outperforming the Dow Jones index's 2,300% increase during the same period [1][8]. Company Overview - Tempus AI, founded in 2015, focuses on AI-enabled precision medicine by integrating clinical and molecular data to accelerate diagnostics, therapy selection, and drug development [2][9]. Business Segments - The company's operations are divided into two main segments: - **Diagnostics**: Provides genomic sequencing and personalized diagnostic recommendations through its own laboratories, with a revenue of approximately $9.55 billion, reflecting a year-over-year growth of about 111%, driven primarily by increased oncology and genetic testing volumes [3][5]. - **Data and Applications**: Licenses its extensive medical database and AI algorithms to pharmaceutical companies and research institutions, generating around $3.16 billion in revenue, which represents a 31% year-over-year increase, mainly driven by data licensing [3][6]. Financial Performance - Tempus AI reported approximately $12.7 billion in revenue for the previous year, marking an overall year-over-year growth of about 83% [4][11]. Analyst Ratings - TD Cowen reaffirmed a "Hold" rating for Tempus AI in December, setting a target price of $88, with analysts optimistic about the company's long-term prospects in the medical AI sector, particularly regarding its structured, large-scale medical datasets that enhance pharmaceutical research efficiency [7][11].

Core Insights - The pet medical industry is undergoing a transformation driven by technological innovation, professional talent support, and a cohesive industrial ecosystem [2][4][6] Group 1: Technological Innovation - The aging of pets and increasing health awareness among pet owners are leading to a rise in complex diseases such as malignant tumors and neurological disorders [12][13][15] - Traditional diagnostic methods face limitations, prompting a shift towards molecular diagnostic technologies, which enable precise screening for genetic diseases and targeted gene mutation detection for tumors [20][21] - Advanced imaging techniques, including high-frequency ultrasound, high-field MRI, and AI algorithms, achieve over 95% accuracy in identifying small lesions, facilitating a transition from experience-based to precision medicine [23][24][26] Group 2: Talent Development - There is a significant shortage of veterinary professionals, with a national gap of 300,000 veterinarians and a lack of specialized talent in areas such as ophthalmology and oncology [29][33] - The current educational system produces only 30% of graduates entering the pet clinical field, with traditional curricula lacking sufficient focus on pet diagnostics [35][36] - Proposed solutions include a three-dimensional model for team building, management, and training, emphasizing the need for practical, hands-on training and collaboration among team members [41][44][46] Group 3: Ecosystem Upgrade - The pet consumption market in urban China is projected to reach 300.2 billion yuan by 2024, with the Greater Bay Area accounting for 10% of national pet medical institutions, highlighting its potential as an investment hub [49][50] - Trends in the pet economy include high-end consumption, technological integration, and cross-industry collaborations, with significant growth expected in high-end food and specialized medical services [54][55] - The Greater Bay Area is positioned as a core engine for the pet medical industry, with a focus on specialized medical institutions and high-end veterinary hospitals as key investment areas [57][62]

来源：科技日报 科技日报记者 赵汉斌 记者25日从昆明理工大学获悉，该校灵长类转化医学研究院团队近期研发的一种新型动态滑环水凝胶， 集伤口监测、精准适配、药物缓释等多种功能于一体，为再生医学与精准医疗领域提供了全新解决方 案。相关研究成果发表于国际期刊《先进医疗材料》。 这种新型水凝胶，采用超分子主—客体相互作用机制构建，核心由两种自主研发的材料组分构成：一种 是四臂聚乙二醇双酪氨酸，作为客体组分；另一种是经精氨酸-甘氨酸-天冬氨酸肽功能化修饰的超支化 聚甘油修饰α-环糊精，作为主体组分。两种组分通过特殊相互作用形成动态网络结构，赋予水凝胶剪切 变稀与快速自修复的独特特性。 这种设计，让水凝胶具备了多重实用功能。在临床应用中，它可实现室温下的挤出式三维打印，精准适 配不同形状的复杂创面，解决了传统医疗材料难以贴合不规则伤口的难题。同时，水凝胶中的双酪氨酸 核心使其拥有pH响应荧光传感功能，可通过荧光强度的变化，实时反馈伤口微环境的pH值波动，为医 生及时判断伤口是否发生感染、炎症程度提供了可视化依据，避免了传统检测方法的滞后性。 此外，超支化聚甘油修饰技术的应用，显著提升了水凝胶对妥布霉素等抗菌药物的负载能力 ...

Core Viewpoint - The National Medical Insurance Administration has released a guideline to standardize pricing for surgical robots and other advanced medical technologies, aiming to facilitate the clinical application of innovative medical technologies and promote a shift towards precision medicine [3][4]. Group 1: Pricing Guidelines - The guideline establishes 37 pricing items, including 5 additional charges and 1 expansion item, covering key technologies such as 3D printing, imaging enhancement, energy devices, intraoperative guidance, surgical robots, and remote surgery [3]. - The pricing framework focuses on the clinical value of new technologies rather than the equipment or surgical site, allowing for a more equitable and transparent pricing model [6][22]. - The guideline introduces a tiered pricing system based on the level of participation and precision of surgical robots, encouraging their use in complex surgeries while preventing misuse in low-value scenarios [6][25]. Group 2: Impact on Remote Surgery - The guideline includes a separate pricing item for remote surgery, facilitating its transition from exploration to practical application [7]. - Remote surgery is particularly significant in emergency situations, such as cardiovascular diseases, where timely intervention is critical [8]. - The establishment of a payment framework for remote surgery is expected to enhance access to quality medical resources across regions, benefiting patients significantly [10][21]. Group 3: Encouragement of Innovation - The release of the guideline signals a clear intent from the government to incentivize continuous innovation in the high-end medical equipment sector [11][12]. - Companies are expected to gain confidence in investing in research and development due to the stable policy environment created by the guideline [12]. - The guideline aims to create a commercial logic loop that supports the sustainable development of innovative medical technologies [11][14]. Group 4: Market Dynamics - The market for surgical robots in China is expected to grow significantly, with domestic market share projected to increase from 32.61% in 2023 to 48.89% in 2024 [17]. - Despite the growth, the overall penetration of robotic surgeries remains low compared to countries like the United States, indicating substantial room for expansion [17]. - The establishment of a unified payment framework is anticipated to activate the existing market for surgical robots, leading to potential growth for companies already holding market share [17]. Group 5: Balancing Costs and Innovation - The guideline aims to balance the need for high-level innovation with the financial burden on patients by establishing pricing boundaries [22][25]. - It specifies that devices with multiple functionalities will be charged based on the highest service price, ensuring fair compensation for advanced capabilities [23][24]. - The National Medical Insurance Administration will guide local agencies in setting reasonable pricing standards, reflecting the value of technical services [26][27].